Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VCYT vs FATE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
VCYT Overall Winner
6-Pillar Tally: VCYT 5 – 1 FATE
Matrix Metrics: VCYT 8 – 2 FATE
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FATE carries 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin).
- Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FATE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VCYT vs FATE
VCYT
Head-to-Head Winner
Veracyte, Inc.
$24.01
-1.32% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
3.01β · 199% Vol
Unified Composite Score
49.1
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
FATE
Fate Therapeutics, Inc.
$1.14
-10.94% 1D
Market Cap
$155.7M
TTM Revenue
$4.8M
Forward P/E
N/M
Beta / 30D Vol
2.16β · 104% Vol
Unified Composite Score
43.0
HOLD
Tech 25.0
Fund 47.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 FATE)
1. Valuation Multiples
VCYT
Forward P/E
15.3x
N/M
Trailing P/E
15.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.1x
39.2x
2. Growth & Scale
VCYT
Revenue Growth (YoY)
+15.1%
+9.2%
Earnings Growth (YoY)
+58.3%
+0.0%
TTM Revenue (USD)
$582M
$4.8M
Market Cap
$2.0B
$155.7M
3. Profitability & Quality
VCYT
Gross Margin
74.2%
N/A
Operating Margin
15.0%
-2736.9%
Net Profit Margin
21.8%
0.0%
Return on Equity (ROE)
9.4%
-67.8%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
$162M
-$107M
Cash Flow Margin
27.8%
N/A
Net Cash / Leverage
$159M Net Cash
$31M Net Debt (0.56x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FATE
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
197.3% (47th %ile)
169.0% (20th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
1.52x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
VCYT
OpEx & R&D Intensity
59.2% of Rev ($344M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VCYT (8) vs FATE (2)| Institutional Metric | VCYT | FATE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.0B | $155.7M | VCYT | |
| Trailing P/E Ratio | 15.8x | N/M | VCYT | |
| Forward P/E Ratio | 15.3x | N/M | VCYT | |
| Revenue Growth (YoY) | +15.1% | +9.2% | VCYT | |
| Operating Margin (TTM) | 15.0% | -2736.9% | VCYT | |
| Net Profit Margin | 21.8% | 0.0% | VCYT | |
| Return on Equity (ROE) | 9.4% | -67.8% | VCYT | |
| 52-Week Range Position | 5% ($22–$61) | 8% ($1–$3) | FATE | |
| Beta / 30D Volatility | 3.01β · 199% Vol | 2.16β · 104% Vol | FATE | |
| Unified Institutional Score | 49.1 / 100 (HOLD) | 43.0 / 100 (HOLD) | VCYT | |
| Trailing 12M Revenue (USD) | $582M | $4.8M | Scale | |
| Gross Profit Margin (TTM) | 74.2% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.1x EV/Rev | N/M PEG · 39.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $162M ($159M Net Cash) | -$107M ($31M Net Debt (0.56x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FATE +8.01 pp
3M Horizon
VCYT +14.49 pp
6M Horizon
FATE +8.04 pp
1Y Horizon
FATE +54.66 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VCYT Revenue | FATE Revenue | VCYT Op. Margin | FATE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $90M | $0M | -24.2% | -1415.4% | VCYT |
| FY2019 | $120M | $10M | -12.6% | -943.1% | VCYT |
| FY2020 | $120M | $30M | -30.1% | -407.5% | VCYT |
| FY2021 | $220M | $60M | -37.3% | -388.6% | VCYT |
| FY2022 | $300M | $100M | -13.9% | -320.2% | VCYT |
| FY2023 | $360M | $60M | -23.8% | -299.9% | VCYT |
| FY2024 | $450M | $10M | 3.6% | -1542.6% | VCYT |
| FY2025 | $520M | $10M | 11.2% | -2222.4% | VCYT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FATE
BREAKDOWN
Current IV
169.0%
IV Percentile
20th %ile
Put/Call OI Skew
1.52x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact FATE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
FATE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VCYT vs FATE Key Questions & Quantitative Answers
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FATE carries 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FATE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with FATE at +9.2% YoY revenue growth and +0.0% YoY earnings growth on $4.8M TTM revenue (N/A gross margin, -2736.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while FATE shifted +0.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FATE.
VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas FATE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 39.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus FATE (-67.8% ROE) capital efficiency.
In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, FATE carries 169.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.52x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 104% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FATE vs VCYT · Reverse Pair
VCYT vs CDNA
· Sector Peer
VCYT vs TWST
· Sector Peer
VCYT vs TXG
· Sector Peer
FATE vs BEAM
· Sector Peer
FATE vs TWST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem